Vinas Florent, Ben Hassen Ikram, Jabot Laurence, Monnet Isabelle, Chouaid Christos
Service de pneumologie et de pathologie professionnelle, Centre Hospitalier Intercommunal Créteil, Créteil, France.
Clin Respir J. 2016 May;10(3):267-71. doi: 10.1111/crj.12217. Epub 2014 Nov 3.
The impact of diagnosis and treatment delays for non-small cell lung cancer management is poorly understood, even if the literature on the subject is currently increasing in importance. We have few indicators that can serve as reference for quality assurance actions. The objective of this review was to review the literature on the subject.
A literature search, using the words 'human lung cancer delay' and 'human lung cancer waiting time', was undertaken in Medline database.
Several studies analyzed these delays mostly in a monocentric setting. There is an important variability in the definition of these delays, in the collection methods and in the results obtained. However, it seems distinctly clear that long delays are frequently observed in less symptomatic patients and, therefore, are accompanied by better prognosis.
More standardized definitions and procedures to calculate time intervals between cancer diagnosis and treatment should be implemented to better understand the delays of lung cancer management.
尽管目前关于非小细胞肺癌管理中诊断和治疗延迟的文献重要性日益增加,但对此的了解仍很有限。我们几乎没有可作为质量保证行动参考的指标。本综述的目的是回顾该主题的文献。
在Medline数据库中使用“人类肺癌延迟”和“人类肺癌等待时间”进行文献检索。
多项研究大多在单中心环境中分析了这些延迟。这些延迟的定义、收集方法和所得结果存在很大差异。然而,很明显,在症状较轻的患者中经常观察到较长的延迟,因此,其预后较好。
应采用更标准化的定义和程序来计算癌症诊断与治疗之间的时间间隔,以更好地了解肺癌管理中的延迟情况。